HOME >> MEDICINE >> NEWS
Free antiretroviral therapy key to success of AIDS treatment in developing countries

HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.

HAART has substantially improved the prognosis of HIV-infected patients who have access to these drugs. HAART is being scaled up in developing countries but several factors could limit the effectiveness of the therapy in resource-poor settings.

In this study the researchers compared the ART-LINC Collaboration--a network of 18 HAART programmes in Africa, Asia, and South America--with a similar network of 12 HAART programmes in Europe and North America. They found that mortality was higher in low-income settings than in high-income settings. Patients in low-income countries had lower CD4 cell counts (indicating an increased risk of infection) and more advanced clinical disease when they started treatment. However, the authors state that this only partly explains the higher mortality. They believe accompanying illnesses (comorbidities) such as tuberculosis that are present in many low-income settings may have increased mortality. They also found that the provision of treatment free of charge in low-income settings was strongly associated with lower mortality.

Author Dr Matthias Egger (University of Berne, Switzerland) concludes: "Antiretroviral therapy is feasible and effective in low income settings, but, compared with industrialized countries, mortality is high in the first months. Eligibility for antiretroviral treatment and the need for treatment of tuberculosis should be determined earlier, and HAART should be started before serious comorbidities develop."

In an accompanying Editorial, The Lancet comments: "The start of th
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
9-Mar-2006


Page: 1 2

Related medicine news :

1. Study shows interruption of antiretroviral therapy increases risk of disease and death
2. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
3. Sub-Saharan Africans with HIV may achieve favorable levels of antiretroviral therapy adherence
4. Saving antiretroviral treatment in long-term HIV-positive patients
5. Access to antiretrovirals unlikely to reduce HIV infection rates
6. Study sets new gold standard for initial antiretroviral treatment of HIV infection
7. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
8. HIV mortality in India drops with introduction of generic antiretroviral therapy
9. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS
10. Chemotherapy with bevacizumab increases risk of blood clots in arteries
11. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... “surprising habits” that may sometimes lead to, or worsen, varicose veins in some ... Center notes that, while avoiding certain not-so-good practices, like excessive sitting or standing, ...
(Date:7/18/2017)... Massachusetts (PRWEB) , ... July 18, 2017 , ... ... medical device compliance and commercialization, has just announced two more sessions of its ... usability engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the ...
(Date:7/18/2017)... ... 2017 , ... An inventor from Anacortes, Wash., knows the difficulties and indignity ... hot flashes, and I suffer from anxiety and vertigo on top of that," she ... and about." INSTA-FAN meets that need. , This device enables a woman in menopause ...
(Date:7/18/2017)... ... July 18, 2017 , ... FCPX LUT Berlin for ... any media. FCPX LUT Berlin includes 60 different color-grade presets, giving FCPX users numerous ... vignettes and blurs to emphasize each subject, plus much more. FCPX LUT Berlin is ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... for parents and camp staff to ensure children are protected from Lyme and ... this year, children are at an increased risk not only for the tick-borne ...
Breaking Medicine News(10 mins):
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)... 30, 2017  AVACEN Medical (AVACEN) announced the publication of new ... the use of its AVACEN Treatment Method to significantly ... ... AVACEN Medical ... widespread pain. It affects approximately 200 to 400 million people worldwide according ...
(Date:6/27/2017)... , June 27, 2017  Therapix Biosciences Ltd. ... pharmaceutical company specializing in the development of cannabinoid-based drugs, ... Stock Market Opening Bell in New York, ... honor of its initial public offering (IPO) of American ... in March 2017. Dr. Elran Haber, Ph.D., ...
Breaking Medicine Technology:
Cached News: